An interventional study of Chlamydia, gonorrhea, syphilis, and HIV screening in Chlamydia, Gonorrhea and Hiv, sponsored by Tulane University. Recruiting at 1 site in United States. Open to participants aged 15 Years to 26 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-21.
Sponsored by Tulane University · Not applicable, Interventional, and Screening
This study includes testing for four STIs (chlamydia, gonorrhea, syphilis, and HIV) at no cost. If positive, individual subjects will also be counseled and offered options for treatment for themselves and their sex partners that may include no cost expedited treatment and the option to be rescreened 3 months after treatment.
134 studies on the registry are indexed under Chlamydia Infections; 23 are open to participants now.
This study's planned enrollment of 2,322 is above the median of 600 across 94 interventional studies indexed under Chlamydia Infections.
Browse Chlamydia Infections studies →Tulane University is the lead sponsor of 96 studies on the registry; 23 are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 5 (56%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Community screening of individuals for chlamydia and gonorrhea is not normally done. We are testing to see if this intervention will impact the rates of chlamydia among women.
Other: Chlamydia, gonorrhea, syphilis, and HIV screening
Individuals aged 15-26 years old will be tested for chlamydia, gonorrhea, HIV, and syphilis at community based venues. Individuals who test positive for chlamydia and gonorrhea and their sexual partners will be offered expedited treatment at participating pharmacies. Individuals who test positive will be asked to be rescreened for Ct/GC at 3 months post treatment.
Rate of chlamydia in women
Primary outcome
Time frame: up to 60 months
Index participant medication pickup rate
Percentage of index participants who obtain their prescribed medication from a partnering pharmacy among all index participants who report intending to pick up the medication. Medication receipt will be determined from pharmacy billing records. Rates will be calculated monthly.
Time frame: up to 60 months
Partner medication pickup rate
Percentage of partners who obtain their prescribed medication from a partnering pharmacy among all partners reported as intending to pick up the medication. Medication receipt will be determined from pharmacy billing records. Rates will be calculated monthly.
Time frame: 60 months
Self reported treatment of index participants and partners
Number and percentage of index participants who report that they and all applicable partner(s) received treatment. The denominator will include index participants who provide follow-up information about their own and their partner(s)' treatment status.
Time frame: 60 months
Plan to share: Yes — We will provide de-identified data to persons who submit a reasonable request with appropriate institutional approval after the primary and secondary request questions have been published.
Supporting information: Statistical analysis plan, Informed consent form
Time frame: IPD and supporting information will be available from 2030 to 2033 (3 years).
Access criteria: Any person with IRB approval from their institution who has a coherent plan for analysis can be provided with a CSV file and coding guide in a de-identified format.
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Tulane University